Diroton (lisinopril) tablets 5 mg. №28

Description

Diroton 5 mg. №28 Storage
active substance: lisinopril;

1 tablet contains 5 mg or 10 mg or 20 mg of lisinopril as lisinopril dihydrate;

Diroton 5 mg. №28 excipients: magnesium stearate; talc; mannitol (E 421); corn starch; calcium hydrogen phosphate dihydrate.

Diroton 5 mg. №28 Dosage form
Tablets.

Basic physical and chemical properties:

Diroton®, tablets of 5 mg:

flat tablets of white or almost white color, round with a facet, with an engraving “5” on the one hand and a line – on the other;

Diroton®, tablets of 10 mg:

quadrangular, slightly biconvex tablets of white or almost white color, engraved with “10” on one side and a dash on the other;

Diroton®, tablets of 20 mg:

pentagonal biconvex tablets of white or almost white color, engraved with “20” on one side and a dash on the other.

Pharmacotherapeutic group
Angiotensin-converting enzyme (ACE) inhibitors.

ATX code C09A A03.

Pharmacological properties

Pharmacodynamics.

Lisinopril is a peptidyl dipeptidase inhibitor. It inhibits ACE, which is the catalyst for the conversion of angiotensin I to a vasoconstrictor peptide, angiotensin II. Angiotensin II also stimulates the secretion of aldosterone by the adrenal cortex. ACE inhibition leads to a decrease in the concentration of angiotensin II, which leads to a decrease in vasoconstrictive activity and a decrease in aldosterone secretion. The latter decrease may lead to an increase in serum potassium.

Because the mechanism by which lisinopril lowers blood pressure is thought to be primarily inhibition of the renin-angiotensin-aldosterone system (RAAS), lisinopril lowers blood pressure even in hypertensive patients with low renin levels. ACE is identical to kinase II, an enzyme that degrades bradykinin. It remains unclear whether elevated levels of bradykinin, a potent vasodilator peptide, are important in the therapeutic effects of lisinopril.

In addition to lowering blood pressure, lisinopril reduces albuminuria due to changes in histology and hemodynamics of the glomerular apparatus of the kidneys. Lisinopril treatment did not affect glycemic control, as evidenced by the lack of significant effects on glycosylated hemoglobin (HbA1c) levels.

Plays a positive role in restoring the function of damaged endothelium in patients with hyperglycemia.

Indication
Hypertension.
Heart failure (symptomatic treatment).
Acute myocardial infarction (short-term treatment for 6 weeks of hemodynamically stable patients no later than 24 hours after acute myocardial infarction).
Treatment of kidney disease in patients with hypertension, type II diabetes mellitus and initial nephropathy.

Contraindication
Hypersensitivity to the active or excipients of the drug.
Hypersensitivity to any other ACE inhibitor.
History of angioneurotic edema associated with previous treatment with other ACE inhibitors.
Hereditary or idiopathic angioneurotic edema.
Pregnant women or women planning to become pregnant (see “Use during pregnancy or breast-feeding”).
Breastfeeding period.
Concomitant use of Diroton® with aliskiren-containing drugs in patients with diabetes mellitus or renal insufficiency (glomerular filtration rate <60 ml / min / 1.73 m2).